Results 261 to 270 of about 33,392 (283)
Some of the next articles are maybe not open access.
Biomacromolecules, 2010
Thermoresponsive oligo(ethylene glycol)-based copolymers were investigated for trypsin conjugation. These copolymers have been synthesized by atom transfer radical polymerization of 2-(2-methoxyethoxy)ethyl methacrylate (MEO(2)MA) with oligo(ethylene glycol) methyl ether methacrylate (OEGMA(475), M(n) = 475 g.mol(-1)) at 60 degrees C in the presence of
Zarafshani, Z., Obata, T., Lutz, J.
openaire +3 more sources
Thermoresponsive oligo(ethylene glycol)-based copolymers were investigated for trypsin conjugation. These copolymers have been synthesized by atom transfer radical polymerization of 2-(2-methoxyethoxy)ethyl methacrylate (MEO(2)MA) with oligo(ethylene glycol) methyl ether methacrylate (OEGMA(475), M(n) = 475 g.mol(-1)) at 60 degrees C in the presence of
Zarafshani, Z., Obata, T., Lutz, J.
openaire +3 more sources
Synthesis of Pegylated Immunonanoparticles
Pharmaceutical Research, 2002This work describes the synthesis of pegylated immunonanoparticles by conjugation of an anti-transferrin receptor monoclonal antibody (MAb) to maleimide-grafted pegylated nanoparticles prepared from poly(lactic acid) (PLA) and a bi-functional polyethyleneglycol (PEG).Maleimide-PEG3500-PLA40000 and methoxyPEG2600-PLA40000 copolymers were synthesized by ...
Jean-Christophe, Olivier +4 more
openaire +2 more sources
Clinical Pharmacokinetics, 2001
The use of liposomal carriers and the modification of therapeutic molecules through the attachment of poly(ethylene glycol) [PEG] moieties ('pegylation') are the most common approaches for enhancing the delivery of parenteral agents. Although 'classical' liposomes (i.e.
J M, Harris, N E, Martin, M, Modi
openaire +2 more sources
The use of liposomal carriers and the modification of therapeutic molecules through the attachment of poly(ethylene glycol) [PEG] moieties ('pegylation') are the most common approaches for enhancing the delivery of parenteral agents. Although 'classical' liposomes (i.e.
J M, Harris, N E, Martin, M, Modi
openaire +2 more sources
Process for protein PEGylation
Journal of Controlled Release, 2014PEGylation is a versatile drug delivery technique that presents a particularly wide range of conjugation chemistry and polymer structure. The conjugated protein can be tuned to specifically meet the needs of the desired application. In the area of drug delivery this typically means to increase the persistency in the human body without affecting the ...
David, Pfister, Massimo, Morbidelli
openaire +2 more sources
Ligand-installed PEGylated bionanosphere
IEE Proceedings - Nanobiotechnology, 2005The synthesis of poly(ethylene glycol)-b-poly(2-N,N-dimethylaminoethylmethacrylate) processing an acetal group at the PEG chain end (acetal-PEGPAMA) is reported. The obtained acetal-PEGPAMA block copolymer was found to reduce tetrachloroauric acid at room temperature to produce gold nanoparticles. The size of these nanoparticles was controllable in the
Y, Nagasaki, K, Kataoka
openaire +2 more sources
International Journal of Peptide and Protein Research, 1995
Conditions have been developed for the site‐specific pegylation (NH2‐terminus, side‐chain and carboxyterminus) of a potent analog of growth hormone‐releasing factor, [Ala15]‐hGRF(1‐29)‐NH2. These pegylated peptides were prepared by solid‐phase peptide synthesis using the Fmoc/tBu strategy, and were fully characterized by analytical HPI.C, amino‐acid ...
A M, Felix, Y A, Lu, R M, Campbell
openaire +2 more sources
Conditions have been developed for the site‐specific pegylation (NH2‐terminus, side‐chain and carboxyterminus) of a potent analog of growth hormone‐releasing factor, [Ala15]‐hGRF(1‐29)‐NH2. These pegylated peptides were prepared by solid‐phase peptide synthesis using the Fmoc/tBu strategy, and were fully characterized by analytical HPI.C, amino‐acid ...
A M, Felix, Y A, Lu, R M, Campbell
openaire +2 more sources
Reviews in gastroenterological disorders, 2002
Interferon therapy for chronic hepatitis C is not a cure, but it is able to decrease the viral load and may decrease the risk of complications (e.g., cirrhosis, liver failure, liver cancer). Pegylation of the interferon increases the amount of time the interferon remains in the body by increasing the size of the interferon molecule. Increasing molecule
openaire +1 more source
Interferon therapy for chronic hepatitis C is not a cure, but it is able to decrease the viral load and may decrease the risk of complications (e.g., cirrhosis, liver failure, liver cancer). Pegylation of the interferon increases the amount of time the interferon remains in the body by increasing the size of the interferon molecule. Increasing molecule
openaire +1 more source